Zsolt P. Harsanyi,
Ph.D., Chairman of the Board of Directors
Dr. Harsanyi has served as a director at Emergent
BioSolutions, Inc., Rockville , MD, USA since August 2004.
Dr. Harsanyi has served as chief executive officer and
chairman of the board of directors of Exponential
Biotherapies Inc., a private biotechnology company, since
December 2004. Dr. Harsanyi was President of Porton
International ("Porton"), a pharmaceutical and vaccine
company based in Washington, D.C. and in London, U.K. Porton
was established in the U.S. as a holding company for Ipsen
Biopharm Ltd., which manufactures Dysport™, and out-licenses
Kogenate™ to Bayer Pharmaceuticals. In 1998 Porton's joint
venture with DynCorp (Reston, Virginia) was awarded a United
States Department of Defense vaccine contract of $322
million. Prior to joining Porton, Dr. Harsanyi was
Vice-President of Corporate Finance at E.F. Hutton, Inc.,
with responsibility for assessing and financing
biotechnology companies. From 1979 to 1981, Dr. Harsanyi
directed the first major assessment of biotechnology for the
U.S. Congress's Office of Technology Assessment, namely,
Impacts of Applied Genetics: Microorganisms, Plants and
Animals. He served, concurrently, as an adviser to the
President's Commission for the Study of Ethical Problems in
Medicine and Biomedical and Behavioral Research. Dr.
Harsanyi has contributed chapters to several books and is
the author of Genetic Prophecy: Beyond the Double Helix.
From 1970 to 1979, he served on the faculty of Cornell
University Medical College and conducted research in
microbial genetics and infectious diseases, and was a
recipient of the Andrew W. Mellon Teacher-Scientist Award.
In addition to his responsibilities at EBI, Dr. Harsanyi is
a trustee of The Immune Disease Institute, an affiliate of
Harvard Medical School. He also serves on the Board of
Emergent BioSolutions, Inc., a biopharmaceutical company
listed on the New York Stock Exchange. Dr. Harsanyi received
his B.A. degree from Amherst College and his Ph.D. degree
from the Albert Einstein College of Medicine in New York
City.
Gabor K. Kalman, Deputy Chairman
Mr. Kalman serves as CEO of N-Gene Inc. since 1997, and has
been Chairman of the Board until 2008. In that time frame,
he has also been managing Director of N-Gene Research Kft,
N-Gene Inc's wholly owned subsidiary in Hungary. He has held
numerous executive positions in entrepreneurial and large
organizations in the medical equipment, biotechnology,
consumer products and printing industry. Among them, Mr.
Kalman has been a founder and Chairman of Biorex Research
and Development Ltd., East Europe's first venture capital
financed high tech research company. Mr. Kalman started his
professional carrier as junior officer in the Hungarian
Foreign Trade Bank in 1977. He holds a B..Sc. from the
Academy for Foreign Trade in Budapest.
Michael J. Brownstein, MD, PhD, CSO & Chairman of the SAB
Dr. Brownstein is Appointed Chief Scientific Officer of
Exponential Biotherapies, Inc. Dr. Brownstein brings over
thirty years of research experience in the fields of
genetics, endocrinology and pharmacology and to the
company's drug development program. He joined the National
Institute of Health to work with Julius Axelrod, recipient
of a Nobel Prize in 1970 for his work in the field of
neuropharmacology, and stayed there after completing his
fellowship. Later Dr. Brownstein served as Chief of the
Laboratory of Cell Biology of the National Institute of
Mental Health ("NIMH"), and was appointed Chief of the
Laboratory of Genetics of the NIMH and the National Human
Genome Research Institute. He has since directed the
functional genomics program at the J. Craig Venter Institute
in Rockville, MD. While at the NIMH, he directed the work in
Bethesda on the Brain Molecular Anatomy Project, the goal of
which was to catalog genes expressed in the nervous system.
Simultaneously, he contributed to the Mammalian Gene
Collection, a trans-institutional effort to clone and
sequence cDNAs corresponding to all human, mouse, and rat
transcripts. He has published more than 200 papers in peer
reviewed journals, has served on several editorial boards
and has served and continues to serve on several scientific
advisory boards including the Lawrence Livermore National
Laboratory and the Translational Genomics Research
Institute. He has also participated in founding several
successful bio-pharmaceutical companies. Dr. Brownstein
earned his bachelor's degree from Columbia University and
completed his medical training at University of Chicago,
where he received his MD and PhD in pharmacology.
Gabor Kovacs
Mr. Kovacs joint the board in 2009 and brings a wealth of
experience in investment and finance. He is founder and CEO
of Bankar Holding Ltd., a private investment bank founded in
1991. Prior to Bankar, he held executive positions at
Citibank in London and Budapest. He started his professional
carrier at the National Bank of Hungary Budapest, in Foreign
Relations Management. In his tenure, Mr. Kovacs has been
engaged in a wide spectrum of activities, among them M&A,
private equity and corporate finance. He received his
education at the Moscow State Institute for Foreign
Relations (IMO), Moscow, Russia.
Peter Literati Nagy, Ph.D.
Dr. Literati serves on the board since 1997 with
responsibility for science. During this period, he also
served as Chief Scientific Officer of N-Gene, and has been
intimately involved in advancing N-Gene´s lead product
BGP-15. Prior to this, he has been scientific director at
various entrepreneurial organizations in Hungary, among them
Biorex Ltd., Budapest, East Europe's first venture capital
financed high tech research company. Dr. Literati spent the
first years of his professional carrier as a research
chemist at Chinoin Pharmaceuticals where he worked on
hydoximic acids such as BGP-15, and at Egis Pharmaceuticals,
both of which are in Hungary. He holds a Ph.D.in chemistry
from Semmelweiss University, Budapest.
Elizabeth B. Vadas, Ph.D.
Dr. Vadas serves on the board since 2004. She runs her own
consulting company InSciTech Inc., providing integrated
solutions for scientific and technical problems faced by
life science companies in the compound selection and product
development areas. Before this, Dr. Vadas was with Merck
Frosst, the Canadian subsidiary of Merck & Co., since 1980.
Her last function has been as Executive Director of
Pharmaceutical Research and Development. She has been
intimately involved in the successful market launch of
multiple marketed products, among them SINGULAIR®, VIOXX®
and ARCOXIA™. Dr. Vadas received her Ph.D. in Physical
Chemistry from McGill University in Montreal. She obtained
her undergraduate degree in colloid and surface chemistry in
Budapest, Hungary.
